The protein Hsp90 is a target of promising anticancer drugs. An analysis of the components of Hsp90 complexes in tumours reveals a path that may lead to predictive assays of drug sensitivity in cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E. & Neckers, L. M. Proc. Natl Acad. Sci. USA 91, 8324–8328 (1994).
Workman, P. Cancer Lett. 206, 149–157 (2004).
Moulick, K. et al. Nature Chem. Biol. http://dx.doi.org/10.1038/nchembio.670 (2011).
Modi, S. et al. Clin. Cancer Res. 17, 5132–5139 (2011).
Sequist, L. V. et al. J. Clin. Oncol. 28, 4953–4960 (2010).
Neckers, L. & Workman, P. Clin. Cancer Res. (in the press).
McClellan, A. J. et al. Cell 131, 121–135 (2007).
Zhao, R. et al. Cell 120, 715–727 (2005).
Maloney, A. et al. Cancer Res. 67, 3239–3253 (2007).
Kamal, A. et al. Nature 425, 407–410 (2003).
Tillotson, B. et al. J. Biol. Chem. 285, 39835–39843 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.F.D. is a PhD student at and P.W. is an employee of the Institute of Cancer Research, which has a commercial interest in Hsp90 inhibitors. P.W. has been involved in a funded research collaboration on Hsp90 inhibitors with Vernalis Ltd. Intellectual property arising from the Hsp90 programme has been licensed to Vernalis and Novartis. P.W. has been a consultant to Novartis.
Rights and permissions
About this article
Cite this article
Darby, J., Workman, P. Many faces of a cancer-supporting protein. Nature 478, 334–335 (2011). https://doi.org/10.1038/478334b
Published:
Issue Date:
DOI: https://doi.org/10.1038/478334b
